相关实验视频

Updated: Jan 17, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

探索针对性结构和核向性多基功能化的抗瘤活动之间的关系 (IV) 产药

Ruihan Li¹, Xuan Yin¹, Chuanke Chong¹

¹School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, Shandong, China.

Molecular pharmaceutics

|September 17, 2025

概括

设计用于以为基础的化疗的聚类药物合体显示,上较高的联结体密度 (如d-CisPt (IV) -TAT) 的前药物,可以因细胞吸收减少而矛盾地降低疗效,强调需要平衡的设计.

科学领域:

生物结合化学生物结合化学
药物输送系统药物输送系统
癌症治疗方法癌症治疗方法

背景情况:

基药物在癌症治疗中至关重要,但患有高系统毒性.
聚胺为向药物输送提供了一个有希望的策略,减轻副作用.
开发与多联合的新(IV) 前药是改善治疗结果的关键.

研究的目的:

设计和合成两个与核向聚结合的金(IV) 前药物.
为了研究不同聚胺连接体密度对前药物反应,细胞吸收和细胞毒性的影响.
阐明这些新型化疗剂的作用机制和结构-活性关系.

主要方法:

有理性的分子合策略合成s-CisPt(IV) -TAT (单替代) 和d-CisPt(IV) -TAT (非替代) (IV) 前药物.
在体外测试以评估合成前药物的反应性,细胞毒性和细胞吸收.
亡试验通过DNA损伤途径确认了作用机制.

主要成果:

与单位替代的s-CisPt(IV) -TAT相比,异位化d-CisPt(IV) -TAT的反应性和细胞毒性较低,尽管功能性更高.
这一反直觉的发现表明,过度的联结可能会阻碍细胞吸收,降低治疗疗效.
这两种 (IV) 前药构造者都通过DNA损伤途径成功诱导了亡.

结论:

精确调整连接体密度对于优化聚类药物联合体的性能至关重要.
结构-活性关系表明,功能密度和生物性能之间的平衡是有效的下一代化疗药物的必要条件.
这项研究为设计具有更好的安全性和有效性配置文件的先进的聚联白金前药提供了宝贵的见解.

关键词:

在Pt药物中,Pt是药物.Pt (((IV) 的意思是这是一种抗瘤药物.这是一种多类聚.定位目标定位目标定位目标

更多相关视频

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Tissue-Drug Binding: Localization of Drugs and its Significance

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...